The area has five units participating in assessment work through:

• providing scientific advice to pharmaceutical companies and the academia
• assessing applications for clinical trials
• coordinating participation in EU assignments
  
• assessing applications for marketing authorisations and indication extensions
  
• horizon-scanning/early detection of pharmaceuticals in the pipeline.
  
• assessing single technology assessments (STA’s) and deciding which medicines should be publicly funded through the general reimbursement scheme
  
• representing Norway in EMA’s scientific committees including CMDh and CMDv